FC
CRBU icon

Franchise Capital’s Caribou Biosciences CRBU Stock Holding History

Franchise Capital’s Portfolio CRBU Stock Details CRBU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-123,436
Closed -$670K – 19
2022
Q2 		$670K Buy
+123,436
New +$944K 0.22% 22

Other funds holding CRBU

PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
EWM
Elmwood Wealth Management Berkeley, California $400M AUM 17.81% 1-Year Est. Return
RCMU
Rokos Capital Management (UK) London, United Kingdom $26.8B AUM 90.85% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return

Franchise Capital's CRBU Position: Q3 2022 in Review

Franchise Capital sold out of Caribou Biosciences (CRBU) in Q3 2022, closing a stake of 123,436 shares — an estimated $670K sold.

Franchise Capital first reported a position in CRBU in Q2 2022 and held it in 1 quarter. The position peaked at $670K in Q2 2022. 113 funds tracked by Wall St. Rank hold CRBU as of Q3 2022.

  • Franchise Capital reported no remaining Caribou Biosciences position as of Q3 2022 after selling out during the quarter.
  • Franchise Capital sold 123,436 Caribou Biosciences shares in Q3 2022, an estimated $670K.
  • Franchise Capital first reported a position in Caribou Biosciences in Q2 2022 and held it in 1 quarter.
  • Franchise Capital's Caribou Biosciences position peaked at $670K in Q2 2022.
  • 113 funds tracked by Wall St. Rank held Caribou Biosciences as of Q3 2022.

Based on Franchise Capital's 13F filing for Q3 2022, filed 15 Nov 2022.